Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Matthew M. Abernathy"'
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 10, Pp n/a-n/a (2024)
Abstract A “one‐step” method which combined the heart rate correction and statistical analysis for conscious nonhuman primate (NHP) QTc assessment was recently published. The principles of this method are applicable to other species. In the cur
Externí odkaz:
https://doaj.org/article/de560e4be2254367ada8e55c591e0580
Autor:
Vincent L. Reynolds, Wei Wang, Meredith A. Steeves, Javed A. Bhalli, LaRonda L Morford, Matthew M. Abernathy, Ronee B. Baracani
Publikováno v:
Burger's Medicinal Chemistry and Drug Discovery
Autor:
Emmanuel Boulay, Loïs S. Miraucourt, Michael K. Pugsley, Matthew M. Abernathy, Ray Chui, Jill Dalton, Marjorie Demers, Noel Dybdal, Elissa Gazaille, Andrea Greiter-Wilke, Peter Hoffmann, Hai Huang, Carrie LaDuke, Kevin Norton, Jennifer B. Pierson, Isabelle Reeves, Brian Roche, Eric I. Rossman, Albert E. Schultze, Hai-Ming Tang, Todd Wisialowski, Simon Authier
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 121:107266
Autor:
David Holdsworth, Derek D. Best, Katarina Haist, Kyle O'Donohue, Anson Phillips, Matthew M. Abernathy, Brian Roche, Derek J. Leishman
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 120:107253
Autor:
Gregory S. Friedrichs, David G. Strauss, Ariane Menard, Jill Steidl-Nichols, Jean-Michel Guillon, Nicolas Gendron-Parra, Simon Authier, Jean-Pierre Valentin, Ray W. Chui, Jennifer B. Pierson, Michael K. Pugsley, Eric I. Rossman, Todd Wisialowski, Matthew M. Abernathy, Emmanuel Boulay, John Koerner, Andrea Greiter-Wilke, Eric Troncy
Publikováno v:
International Journal of Toxicology. 38:23-32
Introduction: Based on the ICH S7B and E14 guidance documents, QT interval (QTc) is used as the primary in vivo biomarker to assess the risk of drug-induced torsades de pointes (TdP). Clinical and nonclinical data suggest that drugs that prolong the
Autor:
Isabel Lushbough, Jean-Pierre Valentin, Vitalina Gryshkova, Simon Hebeisen, Cristian Trovato, Will S. Redfern, Khuram W. Chaudhary, Caiyun Wu, Eric I. Rossman, Kylie A. Beattie, Julie Coulot, Elisa Passini, Yuri A. Kuryshev, Warren D. Anderson, Blanca Rodriguez, Annie Delaunois, Derek J. Leishman, Matthew M. Abernathy, James Kramer, Mark Holbrook
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 3, Pp 1133-1146 (2021)
Clinical and Translational Science, Vol 14, Iss 3, Pp 1133-1146 (2021)
We applied a set of in silico and in vitro assays, compliant with the CiPA (Comprehensive In Vitro Proarrhythmia Assay) paradigm, to assess the risk of chloroquine or hydroxychloroquine‐mediated QT prolongation and Torsades de Pointes (TdP), alone
Autor:
John Koerner, Michael K. Pugsley, William S. Redfern, Ray W. Chui, Jill A. Dalton, Malar Pannirselvam, Matthew M. Abernathy, C Michael Foley, Simon Authier, Gregory S. Friedrichs, Jean-Pierre Valentin, Vijay Urmaliya, Mary Jeanne Kallman, Todd Wisialowski, Tanja S. Zabka, Krystle Correll
Publikováno v:
International journal of toxicology. 39(4)
Introduction: The Safety Pharmacology Society (SPS) conducted a membership survey to examine industry practices related mainly to cardiovascular (CV) safety pharmacology (SP). Methods: Questions addressed nonclinical study design, data analysis metho
Autor:
Junguo Zhou, Paul Butler, Meredith Crosby, Laura Aschenbrenner, Jim Blank, Jonathan G. Moggs, Vincent L. Reynolds, Kyle L. Kolaja, Derek D. Best, Dana Shuey, Matthew M. Abernathy, Terry R. Van Vleet, Chelsea Snyder, Patricia A. Escobar, Timothy K. Hart, Laura Custer
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 117
Pharmaceutic products designed to perturb the function of epigenetic modulators have been approved by regulatory authorities for treatment of advanced cancer. While the predominant effort in epigenetic drug development continues to be in oncology, no
Autor:
John J. Renger, Tiffany Montevideo Whitney, Michael K. Pugsley, Simon Authier, Matthew M. Abernathy, Michael J. Curtis
Safety pharmacology seeks to validate and refine methods for use in preclinical detection of new chemical entity adverse effect liability. It does so in accordance with the scientific method and seeks to organize the strategy of implementation of met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f843c7659b2285e92158ac51f9ba3c4
https://doi.org/10.1016/b978-0-12-812206-8.00015-7
https://doi.org/10.1016/b978-0-12-812206-8.00015-7
Autor:
Derek J. Leishman, Matthew M. Abernathy, Thomas K. Baker, Evan B. Wang, Derek D. Best, Steven K. Engle
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 105:106796